Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Metastatic Breast Cancer × disitamab vedotin × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 HER2-positive Metastatic Breast Cancer 1 HER2-low Breast Cancer 1 Advanced Breast Cancer 1

Interventions

Trastuzumab 3 pyrotinib 2 pertuzumab 2 Fulvestrant 2 tucatinib 1 palbociclib 1 disitamab vedotin 1 atezolizumab 1 RC48 antibody 1 Drug Therapy 1 Docetaxel 1 Capecitabine 1 Alpelisib 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡